Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

O Faergeman

Showing results (161-170 of 170) with videos related to

Pageof 17
Sort By:
You have reached the last page of results.This site can display upto 170 results.
Journal of Internal Medicine|February 10, 2010
Cardiovascular outcomes and their relationships to lipoprotein components in patients with and without chronic kidney disease: results from the IDEAL trialI Holme, R Fayyad, O Faergeman, et al.
Human Mutation|January 1, 1997
Two mutations in the same low-density lipoprotein receptor allele act in synergy to reduce receptor function in heterozygous familial hypercholesterolemiaH K Jensen, T G Jensen, O Faergeman, et al.
Circulation|May 15, 1996
Cholesterol lowering and the use of healthcare resources. Results of the Scandinavian Simvastatin Survival StudyT R Pedersen, J Kjekshus, K Berg, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|April 1, 1997
Phenotypic variation in patients heterozygous for familial defective apolipoprotein B (FDB) in three European countriesP S Hansen, J C Defesche, J J Kastelein, et al.
Archives of Internal Medicine|October 14, 1996
Safety and tolerability of cholesterol lowering with simvastatin during 5 years in the Scandinavian Simvastatin Survival StudyT R Pedersen, K Berg, T J Cook, et al.
The American Journal of Cardiology|August 3, 2000
Follow-up study of patients randomized in the Scandinavian simvastatin survival study (4S) of cholesterol loweringT R Pedersen, L Wilhelmsen, O Faergeman, et al.
Circulation|May 12, 1998
Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S)T R Pedersen, A G Olsson, O Faergeman, et al.
Atherosclerosis|May 1, 1997
A common W556S mutation in the LDL receptor gene of Danish patients with familial hypercholesterolemia encodes a transport-defective proteinH K Jensen, H Holst, L G Jensen, et al.
Neurologia (Barcelona, Spain)|October 8, 2004
[European Guidelines on Cardiovascular Disease Prevention in the Clinical Practice. Third work group of the european societies and other societies on cardiovascular disease prevention in the clinical practice]G de Backer, E Ambrosioni, K Borch-Johnsen, et al.
Journal of Internal Medicine|February 16, 2006
Apo B versus cholesterol in estimating cardiovascular risk and in guiding therapy: report of the thirty-person/ten-country panelP J Barter, C M Ballantyne, R Carmena, et al.
Pageof 17

Showing results (161-170 of 170) with videos related to

Sort By:
Pageof 17
You have reached the last page of results.This site can display upto 170 results.
Journal of Internal Medicine|February 10, 2010
Cardiovascular outcomes and their relationships to lipoprotein components in patients with and without chronic kidney disease: results from the IDEAL trialI Holme, R Fayyad, O Faergeman, et al.
Human Mutation|January 1, 1997
Two mutations in the same low-density lipoprotein receptor allele act in synergy to reduce receptor function in heterozygous familial hypercholesterolemiaH K Jensen, T G Jensen, O Faergeman, et al.
Circulation|May 15, 1996
Cholesterol lowering and the use of healthcare resources. Results of the Scandinavian Simvastatin Survival StudyT R Pedersen, J Kjekshus, K Berg, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|April 1, 1997
Phenotypic variation in patients heterozygous for familial defective apolipoprotein B (FDB) in three European countriesP S Hansen, J C Defesche, J J Kastelein, et al.
Archives of Internal Medicine|October 14, 1996
Safety and tolerability of cholesterol lowering with simvastatin during 5 years in the Scandinavian Simvastatin Survival StudyT R Pedersen, K Berg, T J Cook, et al.
The American Journal of Cardiology|August 3, 2000
Follow-up study of patients randomized in the Scandinavian simvastatin survival study (4S) of cholesterol loweringT R Pedersen, L Wilhelmsen, O Faergeman, et al.
Circulation|May 12, 1998
Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S)T R Pedersen, A G Olsson, O Faergeman, et al.
Atherosclerosis|May 1, 1997
A common W556S mutation in the LDL receptor gene of Danish patients with familial hypercholesterolemia encodes a transport-defective proteinH K Jensen, H Holst, L G Jensen, et al.
Neurologia (Barcelona, Spain)|October 8, 2004
[European Guidelines on Cardiovascular Disease Prevention in the Clinical Practice. Third work group of the european societies and other societies on cardiovascular disease prevention in the clinical practice]G de Backer, E Ambrosioni, K Borch-Johnsen, et al.
Journal of Internal Medicine|February 16, 2006
Apo B versus cholesterol in estimating cardiovascular risk and in guiding therapy: report of the thirty-person/ten-country panelP J Barter, C M Ballantyne, R Carmena, et al.
Pageof 17